Celiprolol in angina pectoris: a controlled study.

This double-blind, placebo-controlled, parallel, multicenter study was designed to evaluate the anti-anginal and anti-ischemic effects of celiprolol in patients with stable, exercise-induced angina pectoris. The study began with a 4-week single-blind, placebo run-in, followed by 4 weeks of double-blind active treatment with celiprolol 200, 400, or 600 mg once daily or placebo, and 1 week of a placebo run-out. Patients studied had a history of chronic, stable angina pectoris and myocardial ischemia (greater than or equal to 1.0 mm ST segment depression) within 3-12 min of treadmill exercise (modified Bruce) after 3 and 4 weeks of placebo. After 2 weeks treatment, treadmill testing results indicated a mean time to myocardial ischemia for patients receiving placebo increased by 0.5 min (8%), whereas the increases for celiprolol 200, 400, and 600 mg were 0.8 min (11%), 2.1 min (33%), and 1.1 min (16%) respectively. Mean time to anginal symptoms for placebo patients was increased by 0.6 min (10%), and for celiprolol patients by 1.8 min (27%), 1.5 min (19%), and 1.0 min (14%) respectively at the 3 dose levels. The maximum exercise double product (heart rate X systolic BP) 24 h after medication, was increased by a mean of 373 (2%) after placebo, but decreased by 3301 (-15%), 3400 (-17%), and 3549 (-16%) for celiprolol 200, 400, and 600 mg respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

RCT Entities:   Population Interventions Outcomes